Certara (NASDAQ:CERT) Shares Up 10.4% – Here’s Why

Certara, Inc. (NASDAQ:CERT)’s stock price traded up 10.4% during trading on Wednesday . The stock traded as high as $11.86 and last traded at $11.86. 208,804 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 795,817 shares. The stock had previously closed at $10.74.

Analyst Upgrades and Downgrades

Several equities analysts have commented on CERT shares. Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Finally, Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Stock Up 12.7 %

The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $1.95 billion, a P/E ratio of -60.50, a P/E/G ratio of 5.86 and a beta of 1.52. The stock’s 50-day simple moving average is $10.86 and its 200-day simple moving average is $11.95.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the business posted $0.06 earnings per share. Certara’s revenue was up 10.7% on a year-over-year basis. As a group, research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CERT. Choreo LLC bought a new position in shares of Certara in the second quarter valued at approximately $348,000. Oppenheimer Asset Management Inc. grew its position in shares of Certara by 45.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 197,724 shares of the company’s stock valued at $2,738,000 after purchasing an additional 61,980 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Certara by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 573,660 shares of the company’s stock worth $7,945,000 after purchasing an additional 43,403 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Certara by 9.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after buying an additional 248,448 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Certara by 9.7% during the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.